drugset / Trial / NCT03733301

A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis

NCT03733301

Phase 3 Completed 329 enrolled Eli Lilly and Company Incyte Corporation · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of baricitinib in combination with topical corticosteroids (TCS) in participants with moderate to severe atopic dermatitis.

Timeline

Start
2018-11-16
Primary completion
2019-07-29
Completion
2019-08-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 2 mg Oral
Subject Baricitinib Small molecule 4 mg Oral

Indications